# Valorphin
> Mediated Wiki article. Canonical URL: https://mediated.wiki/source/Valorphin
> Markdown URL: https://mediated.wiki/source/Valorphin.md
> Source: https://en.wikipedia.org/wiki/Valorphin
> Source revision: 1329170416
> License: Creative Commons Attribution-ShareAlike 4.0 International (https://creativecommons.org/licenses/by-sa/4.0/)
{{Chembox
| ImageFile = Valorphin.png
| ImageClass = skin-invert-image
| ImageSize =
| IUPACName = L-Valyl-L-valyl-L-tyrosyl-L-prolyl-L-tryptophyl-L-threonyl-L-glutamine
| OtherNames =
|Section1={{Chembox Identifiers
| CASNo = 144313-54-2
| CASNo_Ref = {{Cascite|changed|ChemSpider}}
| PubChem = 90470048
| ChemSpiderID = 27470960
| SMILES = C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@@H]3CCCN3C(=O)[C@H](Cc4ccc(cc4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N)O
| StdInChI=1S/C44H60N8O12/c1-22(2)35(45)40(59)50-36(23(3)4)41(60)49-32(19-25-12-14-27(54)15-13-25)43(62)52-18-8-11-33(52)39(58)48-31(20-26-21-46-29-10-7-6-9-28(26)29)38(57)51-37(24(5)53)42(61)47-30(44(63)64)16-17-34(55)56/h6-7,9-10,12-15,21-24,30-33,35-37,46,53-54H,8,11,16-20,45H2,1-5H3,(H,47,61)(H,48,58)(H,49,60)(H,50,59)(H,51,57)(H,55,56)(H,63,64)/t24-,30+,31+,32+,33+,35+,36+,37+/m1/s1
| StdInChIKey = CNYWVXYFCKFXLL-NMUVPRMFSA-N
}}
|Section2={{Chembox Properties
| C=44 | H=61 | N=9 | O=11
| Appearance =
| Density =
| MeltingPt =
| BoilingPt =
| Solubility =
}}
|Section3={{Chembox Hazards
| MainHazards =
| FlashPt =
| AutoignitionPt =
}}
}}
'''Valorphin''', also known as '''VV-hemorphin-5''', is a [naturally occurring](/source/natural_product), [endogenous](/source/endogenous) [opioid](/source/opioid_peptide) [heptapeptide](/source/heptapeptide) of the [hemorphin](/source/hemorphin) family with the [amino acid sequence](/source/peptide_sequence) H-Val-Val-Tyr-Pro-Trp-Thr-Gln-OH (VVYPWTQ).[{{cite journal |vauthors=Maurer R, Römer D, Büscher HH, Gähwiler BH, Thies PW, David S | title = Valorphin: a novel chemical structure with opioid activity | journal = Neuropeptides | volume = 5 | issue = 4–6 | pages = 387–90 |date=February 1985 | pmid = 2860596 | doi = 10.1016/0143-4179(85)90035-6| s2cid = 46078832 }}][{{cite journal |vauthors=Erchegyi J, Kastin AJ, Zadina JE, Qiu XD | title = Isolation of a heptapeptide Val-Val-Tyr-Pro-Trp-Thr-Gln (valorphin) with some opiate activity | journal = International Journal of Peptide and Protein Research | volume = 39 | issue = 6 | pages = 477–84 |date=June 1992 | pmid = 1356941 | doi = 10.1111/j.1399-3011.1992.tb00277.x}}][{{cite journal |vauthors=Blishchenko EY, Sazonova OV, Kalinina OA, etal | title = Family of hemorphins: co-relations between amino acid sequences and effects in cell cultures | journal = Peptides | volume = 23 | issue = 5 | pages = 903–10 |date=May 2002 | pmid = 12084521 | doi = 10.1016/S0196-9781(02)00017-7| s2cid = 44834813 }}] It is produced in the body via [proteolyic](/source/proteolyic) [cleavage](/source/bond_cleavage) of [residues](/source/residue_(chemistry)) 33-39 of the β-chain of [hemoglobin](/source/hemoglobin).[{{cite journal |vauthors=Blishchenko E, Sazonova O, Surovoy A, etal | title = Antiproliferative action of valorphin in cell cultures | journal = Journal of Peptide Science | volume = 8 | issue = 8 | pages = 438–52 |date=August 2002 | pmid = 12212807 | doi = 10.1002/psc.402 | s2cid = 46177846 }}] Valorphin binds preferentially to the [μ-opioid receptor](/source/%CE%BC-opioid_receptor) and produces effects such as [analgesia](/source/analgesia) and [self-administration](/source/self-administration) in animals.[{{cite journal |author1=Blishchenko EYu |author2=Mernenko OA |author3=Mirkina II | title = Tumor cell cytolysis mediated by valorphin, an opioid-like fragment of hemoglobin beta-chain | journal = Peptides | volume = 18 | issue = 1 | pages = 79–85 | year = 1997 | pmid = 9114456 | doi = 10.1016/S0196-9781(96)00248-3|s2cid=11332853 |display-authors=etal}}][{{cite journal |vauthors=Blishchenko EY, Sazonova OV, Kalinina OA, etal | title = Antitumor effect of valorphin in vitro and in vivo: combined action with cytostatic drugs | journal = Cancer Biology & Therapy | volume = 4 | issue = 1 | pages = 118–24 |date=January 2005 | pmid = 15662114 | doi = 10.4161/cbt.4.1.1474| url = http://www.landesbioscience.com/journals/cbt/abstract.php?id=1474| doi-access = free }}] the mediation of which, because they are reversed by [naloxone](/source/naloxone), appears to be dependent on the [opioid receptor](/source/opioid_receptor)s.